Report Company Directory
- Hyperscalers to nearly double AI capex again in 2026. Implications by New Street Research
- Bible 3Q25 – Hyperscale & Cloud: 2026 capex expectations up another 17%, positive initial cue on 2027 by New Street Research
- Moody's Ratings withdraws Juniper Networks' Baa2 senior unsecured ratings by Moody's Investors Service
- 2026 AI Infra. outlook forming: XPU spending catching up with capex, up 95% YoY! by New Street Research
- Q3’25 Previews: AI +ve, Analog -ve, Semicap debatable by BNP Paribas
- Bible 2Q25 – Hyperscale & Cloud: 2026 capex expectations up 19%, $3-4tn AI infra spending by 2030? by New Street Research
- Bible 1Q25 – Hyperscale & Cloud: Inference inflecting, more hints on 2026 growth, green shoots of AI re-platforming by New Street Research
- The Great Replatforming, Part II – The General Theory. Could Jensen just be reasonably optimistic? by New Street Research
- Q2’25 Previews - Analog better, AI reassuring, Consumer pull forward by BNP Paribas
- The Great Replatforming, part I – the Special Theory by New Street Research
- Monthly LMI Update Independent Investment Research by Independent Investment Research
- Feasibility Study Results in December to be a Catalyst for this Junior by Fundamental Research
- FATE: 3Q18 Update: Flush With Cash – Readouts at SITC and ASH by Raymond James
- The Law Offices of Vincent Wong Reminds Investors of an Investigation of Juno Therapeutics, Inc. in Connection with the Sale of the Company to Celgene Corp. by BusinessWire
- INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders by BusinessWire
- JUNO THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders by BusinessWire
- JUNO THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout by BusinessWire
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders by BusinessWire
- JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO by BusinessWire
- A director sold after exercising options/sold 270,250 shares at 46.174USD and by SmartInsider